Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study

被引：0
|
作者：
Li-Nong Ji
Chang-Yu Pan
Ju-Ming Lu
Hong Li
Qiang Li
Qi-Fu Li
Yong-De Peng
Hao-Ming Tian
Chen Yao
Zhi-Gang Zhao
Ru-Ya Zhang
Xiang-Ling Wang
Lei Wang
机构：
[1] Peking University People’s Hospital,
[2] 11 Xizhimen Nan Dajie,undefined
[3] Chinese PLA General Hospital,undefined
[4] Sir Run Run Shaw Hospital,undefined
[5] Zhejiang University Medical College,undefined
[6] The 2nd Affiliated Hospital of Harbin Medical University,undefined
[7] The First Affiliated Hospital of Chongqing Medical University,undefined
[8] Shanghai First People's Hospital,undefined
[9] West China Hospital,undefined
[10] Sichuan University,undefined
[11] Peking University First Hospital,undefined
[12] Henan Provincial People's Hospital,undefined
[13] Beijing Novartis Pharma Co. Ltd,undefined
来源：
Cardiovascular Diabetology | / 12卷
关键词：
VISION study; Vildagliptin; Type 2 diabetes; Study design; DPP-IV inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus
    Agnieszka Strózik
    Arkadiusz Stęposz
    Marcin Basiak
    Magdalena Drożdż
    Bogusław Okopień
    Pharmacological Reports, 2015, 67 : 24 - 31
  • [42] Efficacy, effectiveness and safety of sulphonylurea-metformin combination therapy in patients with type 2 diabetes
    Hermann, LS
    Lindberg, G
    Lindblad, U
    Melander, A
    DIABETES OBESITY & METABOLISM, 2002, 4 (05): : 296 - 304
  • [43] Phase III Study on Efficacy and Safety of Triple Combination (Exenatide/Metformin/Biphasic Insulin Aspart) Therapy for Type 2 Diabetes Mellitus
    Su, Ke
    Lv, Chunmei
    Ji, Zongwen
    Wang, Yishu
    Wang, Haifeng
    Bai, Ying
    Liu, Yaping
    AMERICAN JOURNAL OF THERAPEUTICS, 2018, 25 (06) : E609 - E616
  • [44] A comparison study on efficacy, insulin sensitivity and safety of Glimepiride/Metformin fixed dose combination versus glimepiride single therapy on type 2 diabetes mellitus patients with basal insulin therapy
    Yu, Hea Min
    Kim, Sang Jin
    Chun, Sung Wan
    Park, Keun Young
    Lim, Dong Mee
    Lee, Jong Min
    Hong, Jun Hwa
    Park, Kang Seo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 155
  • [45] Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study
    El Ebrashy, Ibrahim
    El Kafrawy, Nabil
    Raouf, Rana
    Yousry, Diana
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 162
  • [46] A prospective, multicentre study evaluating safety and efficacy of a fixed dose combination of Remogliflozin etabonate, Vildagliptin, and Metformin in Indian patients with type 2 diabetes mellitus (Triad-RMV)
    Prabhat K Agarwal
    Divendu Bhushan
    Amit Bhate
    Sunil Naik
    Shailesh Adwani
    J S Kushwaha
    Sumit Bhushan
    Abhishek Mane
    Rujuta Gadkari
    Sanjay Choudhari
    Saiprasad Patil
    Hanmant Barkate
    Clinical Diabetes and Endocrinology, 10 (1):
  • [47] EFFICACY OF ADD - ON VILDAGLIPTIN THERAPY TO METFORMIN FOR TYPE II DIABETES MELLITUS PATIENTS IN SOUTH INDIAN RESOURCE LIMITED SETTINGS - PILOT STUDY
    Vigneshwaran, E.
    Venkatesh, K.
    Kirankumar, C.
    Rubiya, S.
    Padmanabhareddy, Y.
    Achar, B.
    VALUE IN HEALTH, 2014, 17 (07) : A741 - A741
  • [48] Beyond Metformin: Initiating Combination Therapy in Patients with Type 2 Diabetes Mellitus
    Goldman-Levine, Jennifer D.
    PHARMACOTHERAPY, 2011, 31 (12): : 44S - 53S
  • [49] Nateglinide in Combination with Metformin in Chinese Patients with Type 2 Diabetes Mellitus: A Post-Marketing Surveillance Study
    Yang, Jin-Kui
    Wang, Lei
    CLINICAL DRUG INVESTIGATION, 2013, 33 (03) : 185 - 191
  • [50] Nateglinide in Combination with Metformin in Chinese Patients with Type 2 Diabetes Mellitus: A Post-Marketing Surveillance Study
    Jin-Kui Yang
    Lei Wang
    Clinical Drug Investigation, 2013, 33 : 185 - 191
12345